3 completed, 1 terminated. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow Respiratory Syncytial Virus Prevention: new trials by email Literature Review of Respiratory Syncytial Virus Prevention trials Research Report on Respiratory Syncytial Virus Prevention
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First Year Impact of Nirsevimab on Paediatric Respiratory Syncytial Virus Infection and Hospitalisations in the Australian Capital Territory Respiratory Syncytial Viral (RSV) Infection, Respiratory Syncytial Virus Hospitalizations | Completed | Nicola Irwin | 2355 | 2024-12-01 | 2025-09-19 | |
| A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants Ad26/protein preF RSV Vaccine, Placebo - Respiratory Syncytial Virus Prevention | Phase 3 | Terminated | Janssen Pharmaceutical K.K. | 2192 | 2022-04-01 | 2025-05-23 |
| A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years Ad26.RSV.PreF-based Vaccine - Respiratory Syncytial Virus Prevention | Phase 3 | Completed | Janssen Vaccines & Prevention B.V. | 755 | 2021-11-01 | 2025-05-25 |
| A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old Ad26.RSV.preF-based vaccine - Respiratory Syncytial Virus Prevention | Phase 3 | Completed | Janssen Vaccines & Prevention B.V. | 250 | 2021-10-08 | 2025-05-25 |
Infections (1)
Janssen Vaccines & Prevention B.V. (2) · Janssen Pharmaceutical K.K. (1) · Nicola Irwin (1)
United States (2) · Australia (1) · Japan (1)